Adcendo ApS to Participate in Key Investor Conferences This September Adcendo, a clinical-stage biotech firm, will showcase its innovative ADCs at multiple investor conferences in September, highlighting their advancements in oncology.

Adcendo ApS to Participate in Key Investor Conferences This September #Cancer_Treatment #Denmark #Copenhagen #Adcendo #ADCs

Adcendo ApS to Present at Prominent September Investor Conferences in Boston and New York Adcendo ApS will participate in several key investor conferences this September, showcasing its innovative oncology therapies targeting high unmet medical needs.

Adcendo ApS to Present at Prominent September Investor Conferences in Boston and New York #oncology #Denmark #Copenhagen #Adcendo #ADCs

Adcendo Launches Pioneering ADCE-D01 Trial to Combat Soft Tissue Sarcoma Adcendo has commenced a significant clinical trial evaluating ADCE-D01, a new treatment targeting soft tissue sarcomas with high unmet medical needs, highlighting its innovative approach.

Adcendo Launches Pioneering ADCE-D01 Trial to Combat Soft Tissue Sarcoma #Denmark #Copenhagen #Adcendo #ADCE-D01 #soft_tissue_sarcoma

Adcendo Initiates Phase I/II Trial of ADCE-D01 for Soft Tissue Sarcoma Adcendo has marked a significant milestone by dosing the first patient in its Phase I/II ADCElerate1 trial for ADCE-D01, targeting advanced soft tissue sarcoma.

Adcendo Initiates Phase I/II Trial of ADCE-D01 for Soft Tissue Sarcoma #Denmark #Copenhagen #Adcendo #ADCE-D01 #soft_tissue_sarcoma

Adcendo ApS to Showcase ADCs ADCE-T02 and ADCE-D01 at AACR 2025 Adcendo ApS will unveil data on ADCE-T02 and ADCE-D01, its groundbreaking antibody-drug conjugates, at the AACR Annual Meeting in 2025.

Adcendo ApS to Showcase ADCs ADCE-T02 and ADCE-D01 at AACR 2025 #Denmark #Copenhagen #Adcendo #ADCs #AACR

Adcendo Receives FDA Clearance for Phase I Trial of Innovative ADC Treatment in Cancer Adcendo has achieved a significant milestone, with the FDA approving its IND application for the Phase I Tiffany-01 trial of ADCE-T02, targeting advanced solid tumors.

Adcendo Receives FDA Clearance for Phase I Trial of Innovative ADC Treatment in Cancer #USA #Copenhagen #Adcendo #FDA_Clearance #ADCE-T02

Adcendo ApS Receives FDA Clearance for Phase I Study of ADCE-T02 in Cancer Treatments Adcendo ApS has secured FDA clearance for its IND application, allowing the Phase I Tiffany-01 trial of ADCE-T02 to commence in the U.S., targeting advanced solid tumors.

Adcendo ApS Receives FDA Clearance for Phase I Study of ADCE-T02 in Cancer Treatments #USA #FDA_Approval #Copenhagen #Adcendo #ADCE-T02

Adcendo ApS Completes $135 Million Series B Financing to Enhance ADC Development for Cancer Treatments Adcendo, a biotech company, raised $135 million in Series B financing to accelerate its development of antibody-drug conjugates designed for difficult cancers.

Adcendo ApS Completes $135 Million Series B Financing to Enhance ADC Development for Cancer Treatments #Denmark #Copenhagen #Adcendo #ADC #Cancer_Treatments

Adcendo Secures $135 Million in Oversubscribed Series B Financing to Propel ADC Developments Adcendo ApS has successfully raised $135 million in its Series B funding round, enabling significant advancements in antibody-drug conjugate therapies for cancer treatment.

Adcendo Secures $135 Million in Oversubscribed Series B Financing to Propel ADC Developments #Denmark #Copenhagen #Adcendo #Healthcare_Investment #Biotech_Revolution